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Prevention and treatment of Encephalitozoon cuniculi infection
in rabbits with fenbendazole
Abstract
The efficacy of fenbendazole for preventing an experimental infection of Encephalitozoon cuniculi and
for eliminating the spores from the central nervous system of naturally infected rabbits was investigated.
Fenbendazole (20 mg/kg bodyweight daily) was administered from seven days before until two or 21
days after rabbits had been infected orally with 10(6) spores of E. cuniculi. Both regimens were
effective in preventing the establishment of the parasites, as demonstrated by negative parasitic-specific
serology and by the failure to isolate the parasite from brain tissue. In naturally infected, seropositive
rabbits, parasites were successfully isolated from seven of nine untreated animals, but not from the brain
tissue of eight animals treated with fenbendazole-medicated pellets for four weeks.
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The efficacy of fenbendazole for preventing an experimental infection of Encephalitozoon cuniculi and for
eliminating the spores from the central nervous system of naturally infected rabbits was investigated.
Fenbendazole (20 mg/kg bodyweight daily) was administered from seven days before until two or 21 days
after rabbits had been infected orally with 106 spores of E cuniculi. Both regimens were effective in
preventing the establishment of the parasites, as demonstrated by negative parasitic-specific serology and
by the failure to isolate the parasite from brain tissue. In naturally infected, seropositive rabbits, parasites
were successfully isolated from seven of nine untreated animals, but not from the brain tissue of eight
animals treated with fenbendazole-medicated pellets for four weeks.
ENCEPHALITOZOONOSIS is of worldwide clinical signifi-
cance in laboratory and pet rabbits. Infections with
Encephalitozoon cuniculi can persist without clinical signs for
years, with severe clinical disease occurring only sporadically,
and apparently being unrelated to the age and sex of the
affected animals, although outbreaks of encephalitozoonosis
with 15 per cent morbidity have been reported in young rab-
bits. Spores ofE cuniculi are excreted in the urine of infected
rabbits and the disease is most often transmitted by the inges-
tion of the spores, although intrauterine infection also has
been documented (Canning and Lom 1986).
The clinical signs include stunted growth, central nervous
signs due to granulomatous encephalitis, for example, opistho-
tonus, torticollis, ataxia, hyperaesthesia and nystagmus, eye
lesions, for example, cataract and granulomatous uveitis, and
nephritis (Stiles and others 1997, Ewringmann and Gobel
1999). Differential diagnoses applicable to the neurological
signs include pasteurellosis, toxoplasmosis, otitis media or
interna due to ear mites (Kunstyr and Naumann 1985) and vit-
amin E and/or selenium deficiency. The putative clinical diag-
nosis can be corroborated by specific serology for E cuniculi,
with the immunofluorescent antibody test (IFAT) or an ELISA.
In an uncontrolled study in pet rabbits, treatment with dex-
amethasone in combination with oxytetracyclines and vitamins
resulted in a clinical cure of 10 of the 20 rabbits with neurolog-
ical signs (Ewringmann and Gobel 1999). Apart from main-
taining hygienic standards in units housing rabbits, no
prophylactic strategies have been identified to prevent the intro-
duction of encephalitozoonosis and a strict serology-based test
and slaughter policy has been the only method for eliminating
the parasite from rabbitries (Bywater and Kellett 1978).
A number ofbenzimidazole derivatives including fenben-
dazole are active against Encephalitozoon species in vitro
(Kotler and Orenstein 1999). In rabbits, fenbendazole is used
for anthelmintic treatment (Short and others 1988) and has
no side-effects (Baeder and others 1974). This paper describes
the results of an investigation to assess the prophylactic and
therapeutic effect of fenbendazole in rabbits with experi-
mental E cuniculi infections and in animals with naturally
acquired encephalitozoonosis.
MATERIALS AND METHODS
Parasite cultivation and isolation from tissue
The E cuniculi isolate IPZ:CH-R5870 recovered from a rabbit and
characterised as'rabbit strain' (Mathis and others 1997) was
propagated in primary human lung fibroblast cells (MRC-5) as
described by Mathis and others (1996). Parasite spores were
harvested twice a week from the culture supernatant. After
centrifugation for 10 minutes at 700 g at 20°C, the spores were
resuspended in phosphate buffered saline (PBS), counted in
a Neubauer counting chamber and used immediately.
The spores were isolated from brain tissue as described by
Deplazes and others (1996) and Mathis and others (1996).
The cultures were examined for parasite foci at a magnifica-
tion of 100 to 400. After two months of cultivation without
detectable foci a culture was considered to be negative.
Indirect immunofluorescence antibody test (iFAT)
The IFAT followed the protocol described by Thomas and oth-
ers (1997) and used fresh E cuniculi spores. All the sera were
initially screened at a 1:40 dilution in PBS, and positive sera
were retested in two-fold serial dilutions up to 1:5120.
Medicated pellets
A medicated feed was manufactured (Eberle Nafag; Gossau-
SG) by the addition of4 g/kg fenbendazole (Panacur; Hoechst
Roussel) to a complete mixed feed for rabbits before it was
pelleted. If it is assumed that the rabbits ate 5 g medicated feed
per kg bodyweight per day, they would have received a daily
dose of 20 mg fenbendazole/kg bodyweight.
Prophylactic study
Eight mixed-breed rabbits, four to seven months old and weigh-
ing 2-5 to 3-5 kg, were obtained from the Encephalitozoon-free
colony of the Institute of Parasitology, and used in two sepa-
rate experiments (A and B). In each experiment prophylactic
doses of fenbendazole were administered daily to two rabbits,
beginning seven days before they were infected orally with 106
spores ofE cuniculi in 1 ml PBS. The viability of the parasites was
established by the inoculation ofan aliquot into a tissue culture.
In experiment A, the rabbits received 0-1 ml/kg, twice daily, of
a suspension of fenbendazole (Panacur 10 per cent suspension;
Hoechst Roussel) until 21 days after infection; in experiment
B, the medicated pellets were fed until two days after infection
(5 g/kg daily). The other four rabbits were left untreated as con-
trols. The four rabbits in each experiment were bled from an ear
vein every other week and euthanased after six months.
Therapeutic study
The effect of fenbendazole on established infections was
assessed by comparing the success of attempts to isolate the
parasites from the brains of eight rabbits treated with 5 g
medicated pellets daily for four weeks and from the brains of
nine untreated rabbits. The rabbits were selected from a clin-
ical study of rabbits with E cuniculi-specific antibody titres
above 1:640. They were mixed-breed dwarf rabbits from 14
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FIG 1: Serological
responses of rabbits
infected experimentally
with Encephalitozoon
cuniculi after the
prophylactic
administration of
fenbendazole. In
two independent
experiments (a and b)
the specific antibody
responses after oral
infection with 106
spores of E cuniculi was
measured by IFAT in two
untreated and two
medicated rabbits.
In experiment (a)
fenbendazole was
administered from
seven days before until
21 days after infection,
and in experiment (b)
from seven days before
until two days after
infection. The results of
attempts to isolate the
parasites from brain
tissue and cultivate
them in vitro are given
at the end of each graph
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owners and were examined postmortem within one year after
diagnosis or treatment. They were between four months and
six years of age and weighed 0 5 to 2-5 kg. Ten of them were
males and seven were females and most of them were housed
in groups of two. Six of the eight treated rabbits died of causes
unrelated to encephalitozoonosis (bacterial dysentery in two
cases, stomach ulcers, a fungal infection, Escherichia coli
sepsis, and ileus), and two were euthanased after four weeks
of treatment because they showed persistent neurological
signs consistent with encephalitozoonosis. Four of the nine
untreated rabbits showed neurological signs which were
attributed to encephalitozoonosis, and unrelated clinical
pathology was observed in five cases, leukaemia, sudden
death, ileus, dysentery, and a fractured limb.
RESULTS
Prophylactic study
The four rabbits which were infected experimentally during
their treatment with fenbendazole (either suspension or med-
icated pellets) remained seronegative until 120 days after
infection (Fig 1), and E cuniculi could not be isolated from
their brain tissue. In contrast, all four untreated control rab-
bits seroconverted between day 23 and 40, and developed high
titres (Fig 1). E cuniculi spores were isolated from the brain
tissue of each of them and propagated in vitro.
Therapeutic study
Attempts to isolate E cuniculi from the brain tissue of the 17
naturally infected rabbits were successful in seven of the nine
untreated animals but in none of the eight rabbits treated
with fenbendazole.
DISCUSSION
This paper describes the potentially successful prophylactic
and chemotherapeutic treatment of E cuniculi infections in
rabbits. The oral administration of fenbendazole before exper-
imental infection was effective in blocking the establishment
ofE cuniculi in the rabbit host. The strategic application of fen-
bendazole may be a suitable method for controlling new
Encephalitozoon infections in pet and commercial rabbits.
In the therapeutic study fenbendazole was administered
for four weeks, on the hypothesis that resting spores of the
parasite may not be affected by fenbendazole. The fact that
the treatment eliminated tissue parasite stages was shown by
the reduction of tissue spores to below the detection thresh-
old in all the treated rabbits.
The only drug recommended for the treatment of dis-
seminated Encephalitozoon species infections in human
patients is albendazole (Kotler and Orenstein 1999). In a case
report describing a rabbit with phacoclastic uveitis, treatment
with oral albendazole in combination with topical 1 per cent
prednisolone acetate for eight weeks resulted in the resolution
of the intraocular granuloma (Stiles and others 1997).
However, albendazole is embryotoxic and teratogenic in rats
and rabbits (Kotler and Orenstein 1999). Like albendazole,
fenbendazole is well absorbed and rapidly metabolised to
oxfendazole. Both these compounds were active in vitro
against E cuniculi and E intestinalis (Katiyar and Edlind 1997).
In a preliminary study (data not shown) 16 rabbits with
neurological signs attributed to encephalitozoonosis, and dif-
ferential diagnoses excluded, which had E cuniculi-specific anti-
body titres above 1:640 were treated with medicated pellets
daily for four weeks. Eight animals were free of the neurologi-
cal signs by the end of the treatment but three showed some
residual signs. In two of these animals a slight head-tilt persisted
throughout the study period of three months but the third rab-
bit became clear of signs by this time. Five rabbits responded
poorly to the medication, and owing to the severity of the dis-
ease two were euthanased during the treatment period and
three were euthanased at the end. In these animals, is seems
most likely that the inflammatory lesions associated with the
E cuniculi infection of the nervous system were too severe to be
resolved or compensated for within the observation time. A
similar 50 per cent initial recovery rate was also observed in
response to glucocorticoid treatment of rabbits with central
nervous encephalitozoonosis (Ewringmann and Gobel 1999).
Glucocorticoids may alleviate the neurological signs through
the suppression of the granulomatous inflammation. However,
it is not clear whether this effect is lasting or has any effect on
the parasite burden. In order to improve the clinical treatment
of encephalitozoonosis in rabbits, the combination of fenben-
dazole and glucocorticoids could be valuable and should be
examined in a controlled study.
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'SHORT COMMUNICATIONS
Equine Borna disease
in Japan
H. TANIYAMA, M. OKAMOTO, K. HIRAYAMA,
K. HAGIWARA, R. KIRISAWA, W. KAMITANI,
N. TSUNODA, K. IKUTA
BORNA disease is a fatal disease of the central nervous sys-
tem (CNS) in horses and sheep that was originally recognised
in Borna, Saxony, Germany (Durrwald and Ludwig 1997).
The disease is caused by infection with Borna disease virus
(BDV), and is a non-suppurative encephalomyelitis with a
predilection to involve the grey matter of the cerebral hemi-
spheres and the brainstem (Stitz and others 1993, Gonzalez-
Dunia and others 1997). BDV belongs to a neurotropic,
non-segmented negative-sense, single-stranded RNA virus,
and is the prototype of a new family of the Bornaviridae in
the order Mononegavirales (Gonzalez-Dunia and others
1997). Cases of spontaneous Borna disease in the horse have
been noted only in Germany, Switzerland and Austria
(Lange and others 1987, Weissenbock and others 1998b). A
similar syndrome (called staggering disease) was recently
described in cats (Lundgren and others 1995, Nakamura and
others 1999), dogs (Weissenbock and others 1998a) and
ostriches (Malkinson and others 1995). Furthermore, sero-
logical studies indicate that human BDV infections also exist
(Ludwig and others 1988). Recently, the relationship
between BDV infection and psychiatric disorders, such as
schizophrenia, mood disorder and chronic fatigue syn-
drome, was investigated (Rott and others 1985, de la Torre
and others 1996).
Serum anti-BDv antibodies and BDV RNA in peripheral
blood mononuclear cells (PBMCs) have been demonstrated in
horses that were either clinically normal or pathologically
diagnosed with a disease unrelated to Borna disease in the USA,
Japan, Iran and Sweden (Nakamura and others 1995, Bahmani
and others 1996, Hagiwara and others 1997). However, the
authors have not previously seen evidence of clinical Borna
disease in horses in Japan. This short communication
describes the results ofthe histopathological examination per-
formed on the CNS of two racing horses exhibiting pharyngeal
paralysis, flaccid paresis and motor incoordination.
A seven-year-old thoroughbred mare (horse 1) showed a
sudden onset of pharyngeal paresis and hyperaesthesia in May
1999. Two months later, the horse gradually showed paraly-
sis of the tongue and severe posterior motor incoordination.
The mare was euthanased because of severe cachexia, and a
postmortem examination was performed.
A three-year-old thoroughbred male (horse 2) suddenly
developed flaccid paresis in November 1999. Three months
later the horse showed a severe posterior motor incoordination
and a cervical vertebral malformation accompanied by steno-
sis of the spinal canal at C6 to C7 as demonstrated by radi-
ographic examination. The animal was euthanased because of
neural paralysis, and submitted for postmortem examination.
Serum and cerebrospinal fluid (CSF) antibodies to BDV p40
protein were detected in both animals by immunoblotting as
described by Nakamura and others (1999).A 1:100 dilution of
sera and native CSF showed a clear positive reaction with 40 kDa
BDV p40 antigen. BDV p24 RNA in the brain tissue was detected
by reverse transcriptase (RT)-nested PCR (Nakamura and oth-
ers 1999). BDV p24 RNA-positive signals were detected in the
frontal lobe, mesencephalon and medulla oblongata of horse 1
(Fig 1), and the corpus striatum, hippocampus, and mesen-
cephalon of horse 2. Detection of equine herpesvirus 1 (EHV-
1) DNA by nested PCR was also performed for both animals. The
primers for the glycoprotein B (gB) gene of EHV-1 and condi-
tions for PCR were as described by Kirisawa and others (1993).
EHV- 1 DNA-positive signals were not detected in sample tissues
collected from the corpus striatum, parietal lobe, hippocam-
pus, mesencephalon, pons, cerebellum or spinal cord.
Thin paraffin sections (4 rim) of the brain tissues fixed in
4 per cent paraformaldehyde solution were stained with
haematoxylin and eosin for histological and immunohisto-
chemical evaluation by light microscopy. Neuropathological
lesions were characterised by a non-suppurative encephalitis
dominated by perivascular cuffs consisting of lymphocytes,
macrophages and plasma cells (Fig 2), the presence of inflam-
matory cell infiltrates in the neural parenchyma, neu-
ronophagia, focal gliosis, and scattered axonal degeneration.
Severe lymphocytic cuffs in small vessels were occasionally
associated with a surrounding neural necrosis and an infiltra-
tion of fat granule cells and lymphocytes. Large pyramidal cells
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